Download Radiation Oncology: The Basics by Adam Maier, DO

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Radiation Oncology
The Basics
Adam Maier D.O. , M.B.A
http://clinicalgate.com/basics-of-radiation-therapy-2/Types of Radiation
External Beam (Outside In)
• 3D CONFORMAL
• IMRT
• PROTONS
• ELECTRONS
Brachytherapy
(Inside Out)
http://www.slideshare.net/openmichigan/010709tlawrenceintroradoncologypreclin
It’s a Process
• PLAN
ADULT COLORING BOOKS
http://www.cnn.com/2016/01/06/health/adult-coloring-books-popularity-mental-health/
2.5 mm Slices
Cross-sectional Nodal Atlas: A Tool for
the Definition of Clinical Target Volumes in Three-Dimensional Radiation Therapy Planning. Radiology 1999; 211:815-828
http://logancancer.com/?page_id=41
https://www.researchgate.net/figure/236457344_fig3_Fig-3-Dose-volume-histogram-Optimal-radiation-treatment-plans-balance-tumor-coverage
BREAST UPDTAES
• 16 fraction vs 25 fractions regimen
(plus or minus boost)
• Prone Radiotherapy in selected patients
• Oncotype DCIS
Coming Soon
http://provisionrt.com/prone-breast-radiotherapy/
San Antonio Breast Cancer Symposium 2007
Oncotype DCIS
• RT provides no survival benefit in DCIS
• RT reduces local recurrence by 66% (relative)
• Each woman has her own “risk” of recurrence
• Traditionally based on pathologic factors
– Grade, tumor size, etc
Ohio Health Registry
• Women Age 50 Older
• Low and Intermediate grade DCIS (1-2)
• Adequate Surgical Margins (3 mm)
• Small tumors
• ER/PR positive and willing to take endocrine Tx
Lung SBRT
Stage 1 Lung Cancer
• Multiple Comorbidities
• RT reserved for medically inoperable
candidates
• Historical series patient selection bias
• Why is this important?
Screening
• Low Dose CT Scan
• 55-77 years old
• 30 pack year smoking history
• Current smokers or smoked within 15 years
NLST
Timmerman SBRT
• SBRT 18 Gy x 3 fractions
• Local Control > 90 % at 3 years with SBRT
• 3 year survival of 57 % in T1-T2 patients
• Surgical Series Survival 70%
JAMA 2010
SBRT vs Lobectomy
• Lobectomy IS the current standard of care for
operative candidates with stage 1 NSCLC
• Trials underway comparing SBRT vs lobectomy
• Difficult to accrue patients
STARS AND ROSEL POOLED DATA
•
•
•
•
•
< 4cm
Node Negative
MEDICALLY OPERABLE CANDIDATES
Pooled Date from PROSPECTIVE Phase 3
SBRT vs Lobectomy with Nodal
Dissection/Sampling
• 58 patients (NOT IDEAL)
Roth Lancet Volume 16, No. 6, p630–637, June 2015
SBRT v LOBECTOMY
• 31 SBRT and 27 surgery
• 3 year Overall Survival
– 95% with SBRT (95% CI 85-100)
– 79% with Surgery (95% CI 64-97)
– Not statistically significant
– No grade 4 events with RT
SBRT is very well tolerated
ABSCOPAL EFFECT
• Localized Irradiation of a tumor causes not
only shrinking of the irradiated tumor but also
a shrinking of tumors far from the irradiated
area
ABSCOPAL EFFECT
• HCC patient with lung
mets
• Could not tolerate
sorafenib
• Liver alone was treated
http://www.cureus.com/articles/3216-abscopal-effects-case-report-and-emerging-opportunities
• Presentation of DNA and
Cell Debris
• Apoptosis vs Necrosis
• Fraction Size
• Immune Modulation
• Timing of RT
Palliative Radiotherapy
• 10 vs 5 vs 1 treatment
– Customized to each patient
• Onset of pain relief is identical
• Duration of pain relief similar
• Local control not as good
– Spinal cord, femoral neck lesions, etc
Local Therapy
Local Toxicity
Local Therapy
Radiation Pneumonitis
• Lung and Breast (uncommon)
• 6 weeks to 6 months following completion of
Radiotherapy
• Dry Cough
• Shortness of Breath
• Worse At Night
• Not responding to Antibiotics
• Chest XRAY
Prednisone (often
60 mg/day) for 2
weeks with slow
taper
BREAST TOXICITIES
• Arm Mobility Issues
• Lymphedema
• Pneumonitis
PROSTATE
• Chronic urinary and rectal issues
• Sexual Health
PAIN
• A physician shall not be required to review and assess an
OARRS report when prescribing or personally furnishing an
opioid analgesic, benzodiazepine, or other reported drug
under the following circumstances, unless a physician
believes or has reason to believe that a patient may be
abusing or diverting reported drugs:
• (1) The reported drug is prescribed or personally furnished
to a hospice patient in a hospice care program as those
terms are defined in section 3712.01 of the Revised Code,
or any other patient diagnosed as terminally ill;
• (4) The reported drug is prescribed or personally furnished
for the treatment of cancer or another condition associated
with cancer
The BASICS
• EAT
• DRINK
• SLEEP
• ACTIVITY
• PAIN CONTROL
THANK YOU